A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time - sprookjes - yvandenbroek - TriplyDB

A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time

A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time

http://www.wikidata.org/entity/Q34571082

about

Correlation between trough plasma dabigatran concentrations and estimates of glomerular filtration rate based on creatinine and cystatin C.Enhanced elimination of dabigatran through extracorporeal methods.Evaluation of the chromogenic anti-factor IIa assay to assess dabigatran exposure in geriatric patients with atrial fibrillation in an outpatient setting.The modification of the thrombin generation test for the clinical assessment of dabigatran etexilate efficiency.Non-vitamin K Oral Anticoagulants Versus Warfarin for Patients with Atrial Fibrillation: Absolute Benefit and Harm Assessments Yield Novel Insights.Treating patients on new anticoagulant drugs.

P2860

Q33804810-F80950AF-0027-4634-9755-0E5BDC42096A Q35210137-A27E2812-5D55-4A68-BD31-7DF15A323E5E Q36875879-2DD0ED6F-F574-4C30-88C3-D5B7E08B61FD Q37063974-D2F9C27A-3907-4ED2-98AE-E44C661E5A62 Q38685824-68C8C0BE-6FB1-43BA-B9D4-95624D5A37BC Q42290326-DD84ED56-7C20-4C1B-AB97-58AD593E21F5

P2860

A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time

http://www.wikidata.org/entity/Q34571082

description

2014 nî lūn-bûn

@nan

2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

A proposal for dose-adjustment ...... lation guided by thrombin time

@ast

A proposal for dose-adjustment ...... lation guided by thrombin time

@en

A proposal for dose-adjustment ...... lation guided by thrombin time

@nl

type

label

A proposal for dose-adjustment ...... lation guided by thrombin time

@ast

A proposal for dose-adjustment ...... lation guided by thrombin time

@en

A proposal for dose-adjustment ...... lation guided by thrombin time

@nl

prefLabel

A proposal for dose-adjustment ...... lation guided by thrombin time

@ast

A proposal for dose-adjustment ...... lation guided by thrombin time

@en

A proposal for dose-adjustment ...... lation guided by thrombin time

@nl

P1433

Q34571082-F2523F2F-05CE-40D1-87F7-6003E8EAC998

P1476

Q34571082-9886B661-25F8-462B-B0CE-BD8D29578ABC

P2093

Q34571082-81A9D0B4-F229-4131-A381-A70DE7EE749E

Q34571082-A4920632-7381-4F39-BA09-D4A461E7AD77

Q34571082-B3E26F62-82BA-4B44-9A80-4D298602B25C

Q34571082-C836421B-6C64-4E78-9DD8-5E3E63E3AE73

Q34571082-C9172374-3B47-4D02-8583-2524700886DB

P2860

Q34571082-0472E792-ADF9-4F64-A619-819AD458D885

Q34571082-08185EFB-A365-4F5B-B220-02B14CEADD8B

Q34571082-09F2E5DF-8815-4DAA-AED8-6DFA8AC78F55

Q34571082-0A8E22AC-4E1A-4562-8008-0661CE29AFD6

Q34571082-142887DF-A4D8-4E99-892C-094A71830D48

Q34571082-15344B79-A4A5-487D-BA0D-0A2C9E2F0070

Q34571082-1E131A2C-BD4F-4F25-AF62-3BC62F0547F7

Q34571082-29904CCC-54AD-4C0F-BC63-A254BF036329

Q34571082-2B509EC9-89EE-4B45-A84D-9B9E86C6A443

Q34571082-3445A9E2-F6E7-495A-8C36-06D78F4E2F8C

P304

Q34571082-CA107004-E4D1-41A6-9998-2123674F7C03

P31

Q34571082-9F1E8E5B-EAF4-4127-80DE-FFD2FA1FDF69

P356

Q34571082-5ED20DD1-14D7-46DF-B37F-0CC6A695F997

P407

Q34571082-579BA04E-B4D7-4F5C-9AEC-B20212430AB0

P433

Q34571082-2AC99019-6284-4615-A040-6D8E1943F07C

P478

Q34571082-863A1C3E-671C-4D23-BAEE-A92E270615E1

P577

Q34571082-F5E52870-F528-4E3D-A213-947C48354EA8

P698

Q34571082-432F662B-4201-45A6-A825-E62CC22C95D5

P932

Q34571082-FBFF1950-2590-49AE-B93E-5193183C710C

P356

P1433

British Journal of Clinical Pharmacology

P1476

A proposal for dose-adjustment ...... lation guided by thrombin time

@en

P2093

Daniel F B Wright

http://www.w3.org/2001/XMLSchema#string

David M Patterson

http://www.w3.org/2001/XMLSchema#string

Evan J Begg

http://www.w3.org/2001/XMLSchema#string

Matthew P Doogue

http://www.w3.org/2001/XMLSchema#string

Paul K L Chin

http://www.w3.org/2001/XMLSchema#string

P2860

A specific antidote for dabigatran: functional and structural characterization

Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement

Dabigatran versus warfarin in patients with atrial fibrillation

Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity

Genetic determinants of dabigatran plasma levels and their relation to bleeding

Validation of Clinical Classification Schemes for Predicting Stroke

2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association

Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects.

10 years of oral anticoagulant pharmacogenomics: what difference will it make? A critical appraisal.

A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.

P304

599-609

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BCP.12364

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

78

http://www.w3.org/2001/XMLSchema#string

P577

2014-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24592851

http://www.w3.org/2001/XMLSchema#string

P932

4243910

http://www.w3.org/2001/XMLSchema#string